Additionally, the regulation of HHLA2 expression by the IFN-γ/STAT1 pathway has only been observed in liver cancer; further investigation is required to explore the potential therapeutic effects of targeting this pathway to regulate HHLA2 expression in other gastrointestinal tumors. Here, IFNG is linked to digestive system neoplasm.